Biotech closed the week of October 9 broadly higher (31 of 40 names up over five sessions, 36 of 40 up on Friday alone), with $MRNA closing at a new 52-week high at RSI 72.1 after a 14.21% Friday. Last week's genomics squeeze cooled rather than broke: $GRAL fell from RSI 82.0 to 67.8 and $ILMN and $DNA left the extended band. What broke: $IMVT slid to RSI 20.5 and closed 4.4% below its 200-day average, so the cohort's one oversold name with an intact trend a week ago is now a trend under test. $NKTR and $BMRN stay oversold at RSI 22.9.

Data as of the 2026-10-09 settled close; 40 tickers, every one carrying a 2026-10-09 bar.

The week ended on a broad bid. $XBI and $IBB each gained 3.0% on Friday; $XBI (RSI 46.2) is still 1.0% below its 20-day and -0.43% on the week, while $IBB (50.7) closed on its 20-day, +0.58% on the week. Both stay above their 200-day averages (10.2% and 13.5%) on positive years (+44.36% and +35.8%), so the cohort's long trend is intact and its short trend is repairing. Breadth improved: 19 of 40 names sit below their 20-day average, down from 26 a week ago.

$MRNA is the week's standout: $225.00, +14.21% on Friday on 1.69 times average volume, +18.41% on the week and +65.92% over 30 days, closing at its 52-week high at RSI 72.1. It is 209.8% above its 200-day on a +717.29% year, the most stretched long trend on the board. No driver is on file: its news was last pulled September 30, the October 7 market brief logged its +4.81% day that week as cause unknown, and no October 9 news is on file. $ABBV joined it in the extended band (RSI 71.2, +5.19% on the week, 0.41% below its high, 18.8% above its 200-day).

Last week's genomics squeeze cooled. $GRAL went from RSI 82.0 to 67.8 and lost 1.87% on the week despite a 6.01% Friday; it remains 87.8% above its 200-day on a +97.64% year. Its run has a dated backdrop, not a weekly cause: GRAIL's investor page records the FDA advisory committee vote in favor of approving the Galleri test on September 23. $DNA whipsawed: the October 5 and 6 market briefs logged a 21.3% gain and a 17.16% loss with no cause found, and it added 14.64% on Friday (news last pulled October 6). It is 54.2% above its 200-day but still -14.7% on the year, a bounce that has not repaired the year. $RXRX gained 10.38% on Friday at $4.36; its October 5 jump had a receipt (StocksToTrade tied it to Tempus AI extending their deal to 2029), Friday's does not. $ILMN (62.9) is 67.3% above its 200-day on a +188.41% year and 10.08% below its high.

The damage is in three names. $IMVT fell 9.37% on the week to $30.47 and RSI 20.5, 4.4% below its 200-day ($31.86) with a +74.31% year: a strong year whose long trend is now under test. Its 30-day decline of 21.37% includes Immunovant's September 23 release that IMVT-1402 missed its primary endpoint in cutaneous lupus and that development there would stop; this week's leg has no dated item (news pulled October 3). $NKTR (RSI 22.9) is 36.9% below its 200-day, -43.85% over 30 days and -26.01% on the year: broken. $BMRN (22.9) is 6.6% below its 200-day on a +1.76% year with negative alpha, sitting on its nearest support shelf ($54.24 against a $54.80 close).

• Extended band rotated. A week ago it held $GRAL, $DNA and $ILMN; now it holds $MRNA and $ABBV. None of the 40 is at RSI 80 or higher.
• Capitulation band widened from one name ($NKTR) to three ($IMVT, $BMRN, $NKTR).
• Breadth: below the 20-day, 19 of 40 (26 a week ago); below the 200-day, 13 of 40 (16 a week ago); negative year, 16 of 40 (unchanged).
• Long-trend changes: $IMVT dropped below its 200-day (intact a week ago, now under test). $REGN moved back above its 200-day on a positive year (under test a week ago, now intact). $MDT, $EDIT and $NTLA moved from broken to under test: $MDT is back to its 200-day on a negative year, $EDIT and $NTLA sit above their 200-day averages on negative years.
• Universe unchanged: the same 40 tickers as the October 2 edition.

RSI measures stretch over fourteen sessions: under 30 oversold, 70 and over extended, 80 and over extreme. The long tests decide what a low RSI means: above the 200-day with a positive year is an intact trend (a pullback), one test failed is a trend under test, both failed is broken. A name more than 10% above its 20-day is treated as stretched even with RSI under 70. This board carries price, RSI and trend only, with no insider, fundamental or pipeline layer, so a low RSI is raw screen evidence, not a setup. Sub-$5 shares ($RXRX, $EDIT) carry business risk this board cannot grade.

Tape figures below are live-bound to the desk summaries; the as-of date is shown per row.

$IMVT, $BMRN, $NKTR

Long-trend status: intact (above the 200-day, positive year) none; under test or repairing (one long test failed) $IMVT, $BMRN; broken (below the 200-day, negative year) $NKTR.

$INCY, $NVO, $COGT

Long-trend status: intact (above the 200-day, positive year) $INCY; under test or repairing (one long test failed) $COGT; broken (below the 200-day, negative year) $NVO.

$IONS, $REGN, $DXCM, $SRPT, $RARE, $LEGN, $ALNY, $VRTX, $XBI, $CRSP, $IQV, $BNTX, $MDT, $KYMR, $IBBQ, $IBB, $BEAM, $PTGX, $LLY, $TMO, $AMGN, $DHR, $EDIT, $BIIB, $NTLA, $RXRX, $GILD, $A, $ILMN, $DNA, $ISRG, $GRAL, $ABBV, $MRNA

Of these, RSI 70 or higher: $ABBV, $MRNA

Zones are conditions (a level plus a confirmation), not orders. Levels are live-bound to the desk summaries.

• $IMVT: the line is its 200-day average, which stood at $31.86 on October 9; a close back above that average restores the intact trend, and staying under it means the strong year is being given back. The nearest support shelf sits at $27.69.
• $MRNA at a 52-week high and RSI 72.1, 22.9% above its 20-day: the first close below its 20-day would be the first crack in the run; a driver for Friday's 14.21% is still not on file.
• $GRAL and $ILMN: whether the cooling stops at the 20-day ($115.73 and $258.19) or the genomics leg unwinds further.
• $INCY (RSI 31.4, 5.2% above its 200-day): the one oversold name in an intact trend; the 200-day ($107.21) and the shelf ($104.60) are the floor. Incyte is scheduled to report on October 29 (date estimated).
• $BMRN on its shelf at $54.24: a break below it with RSI under 25 extends a trend already under test. BioMarin is scheduled to report on October 26.
• Funds: $XBI regaining its 20-day ($155.38) would confirm the Friday bid as a turn rather than a one-day pop.

• Tape data: pre-computed desk summary for the biotech universe, as of the 2026-10-09 settled close (biotech-scan).
• News receipts checked: latest (fetched 2026-09-30), DNA (2026-10-06), RXRX (2026-10-05; StocksToTrade, Tempus AI deal extended), GRAL (2026-10-06; GRAIL investor news releases), IMVT (2026-10-03; Immunovant, IMVT-1402 cutaneous lupus topline), NKTR (2026-10-03), BMRN (2026-10-03), ILMN (2026-10-08). None covers an October 9 move.
• Market briefs: 2026-10-05-market-brief (Ginkgo's October 5 gain, Recursion's Tempus receipt), 2026-10-06-market-brief (genomics unwind, cause unknown), 2026-10-07-market-brief (Moderna +4.81%, cause unknown).
• Event calendar: research/stock-events/ checked for 2026-10-03 to 2026-10-09 (no entries for these names); 2026-10-26-bmrn-earnings.md (scheduled), 2026-10-29-incy-earnings.md (estimated). No October 9 captures are on file.
• Prior scan: 2026-10-02-biotech-scan (structure, universe, and its October 2 readings cited as history).